All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/adv melanoma (mML), Ipilimumab (10 mg/kg) vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CheckMate 238, 2017 (REV) 1.15 [0.87; 1.51]
0.96 [0.71 ; 1.31 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 72% 1,633 low not evaluable MFSdetailed results CheckMate 238, 2017 (REV) 1.37 [1.04; 1.80]
1.37 [1.04 ; 1.80 ] CheckMate 238, 2017 (REV) 1 0% 735 NA not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
0.89 [0.66 ; 1.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 (REV) 1.41 [1.18; 1.69]
1.41 [1.18 ; 1.69 ] CheckMate 238, 2017 (REV) 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 (REV) 1.54 [1.21; 1.96]
1.54 [1.21 ; 1.96 ] CheckMate 238, 2017 (REV) 1 0% 906 NA not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
1.19 [0.86 ; 1.63 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
1.31 [0.86 ; 2.00 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable AE (any grade)detailed results CheckMate 238, 2017 (REV) 2.04 [0.81; 5.09]
2.04 [0.81 ; 5.09 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 3.61 [2.72; 4.78]
3.61 [2.72 ; 4.78 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 (REV) 6.88 [4.79; 9.89]
6.88 [4.79 ; 9.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 (REV) 9.18 [5.67; 14.85]
9.18 [5.67 ; 14.85 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CheckMate 238, 2017 (REV) 3.98 [2.35; 6.74]
2.95 [1.81 ; 4.79 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 62% 1,631 low not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CheckMate 238, 2017 (REV) 5.05 [3.67; 6.97]
3.72 [2.02 ; 6.88 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 84% 1,631 low not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
2.35 [0.53 ; 10.46 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
CheckMate 238, 2017 (REV) 8.53 [5.76; 12.63]
4.09 [0.97 ; 17.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 97% 1,631 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
CheckMate 238, 2017 (REV) 11.69 [6.83; 20.02]
5.10 [1.02 ; 25.41 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 96% 1,631 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.07; 59.70]
2.00 [0.07 ; 59.70 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.44 ; 9.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.18 ; 22.14 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.02 [0.45; 36.09]
4.02 [0.45 ; 36.09 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
2.16 [0.96 ; 4.84 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CheckMate 238, 2017 (REV) 6.67 [2.97; 14.99]
3.38 [0.96 ; 11.93 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 85% 1,631 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
2.30 [0.99 ; 5.36 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.37 ; 11.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
CheckMate 238, 2017 (REV) 9.92 [4.91; 20.07]
4.16 [0.79 ; 21.92 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 94% 1,631 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 7.08 [0.87; 57.77]
7.08 [0.87 ; 57.77 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
2.51 [0.48 ; 13.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 6.73 [3.15; 14.39]
6.73 [3.15 ; 14.39 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
1.98 [0.17 ; 22.37 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 14% 1,631 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 1.00 [0.06; 16.00]
1.00 [0.06 ; 16.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
CheckMate 238, 2017 (REV) 5.60 [1.23; 25.41]
2.49 [0.67 ; 9.27 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 55% 1,631 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.28 ; 14.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CheckMate 238, 2017 (REV) 9.85 [2.28; 42.54]
9.24 [2.79 ; 30.59 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CheckMate 238, 2017 (REV) 5.44 [2.07; 14.31]
5.64 [2.50 ; 12.71 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 18.30 [1.06; 316.70]
7.32 [0.82 ; 65.03 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CheckMate 238, 2017 (REV) 10.08 [0.55; 185.02]
2.44 [0.27 ; 22.33 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 40% 1,631 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
4.00 [0.18 ; 89.05 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CheckMate 238, 2017 (REV) 2.85 [1.02; 7.98]
2.75 [1.15 ; 6.58 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 1.00 [0.02; 50.40]
1.00 [0.02 ; 50.40 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 238, 2017 (REV) 8.04 [0.42; 152.61]
8.04 [1.00 ; 64.42 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
CheckMate 238, 2017 (REV) 5.67 [2.16; 14.85]
2.93 [0.75 ; 11.49 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 70% 1,631 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-03 16:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 558
